HealthSTATS was founded in 2000 by Dr. Ting Choon Meng, along with two partners.
Hypertension, commonly referred to as “high blood pressure” is a global medical problem in which the blood pressure is chronically elevated. It has reached epidemic proportions in recent years. The statistics show that around a billion people worldwide have high blood pressure, and over half a billion more will harbour this “silent killer” by 2025. Hypertension is a major risk factor for heart attacks, heart failure, strokes and arterial aneurysm and is a leading cause of renal failure. This translates into millions of deaths from heart disease alone. According to a recent article in Lancet by Franz Messerli et al on “Seminar on Essential hypertension”, the risk of becoming hypertensive during lifetime exceeds a staggering 90% for a person in a developed country.
Despite the advances of medical technology and the continuous offerings of new drugs in the market, hypertension continues to increase in both developed and developing countries. This increase was addressed in a recent Lancet editorial: “Hypertension: uncontrolled and conquering the world”.Driven by the desire to find the missing link and to solve this problem with the patient’s welfare as its cornerstone, Dr. Ting founded HealthSTATS International. This missing link is based on using a combination of 24-hr Ambulatory Blood Pressure Monitoring [ABPM] and Arterial Pulse waveform [A-PULSE] with evidence-based approach to the treatment & management of hypertension and its target organs. It is expected that a combination of this first-of-its-kind approach and its associated technology will significantly reduce the incidence of hypertension globally.
THE MISSING LINK
The company has been granted ISO13485 and ISO9001. HealthSTATS is the first Singapore company to be granted FDA approval for its bio-monitoring device. HealthSTATS key bio-monitoring product, BPro®, has received US FDA, Europe CE (MDD), China SFDA, Australia TGA and Singapore HSA regulatory approvals.
BPro® has been validated independently by the Clinical Trials and Epidemiology Research Unit (CTERU) in compliance with protocols set by the Association for the Advancement of Medical Instrumentation (AAMI) and European Society of Hypertension (ESH) for accuracy.